Get the Stockscreener App
3.11
6.87%
0.20
After Hours:
3.02
-0.09
-2.89%
Jaguar Health Inc stock is traded at $3.11, with a volume of 99,467.
It is up +6.87% in the last 24 hours and down -77.09% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
See More
Previous Close:
$2.91
Open:
$2.91
24h Volume:
99,467
Relative Volume:
1.75
Market Cap:
$1.60M
Revenue:
$11.51M
Net Income/Loss:
$-54.00M
P/E Ratio:
-0.00437
EPS:
-711.8194
Net Cash Flow:
$-23.73M
1W Performance:
-7.30%
1M Performance:
-77.09%
6M Performance:
-92.36%
1Y Performance:
-97.82%
1-Day Range:
$2.91
$3.24
1-Week Range:
$2.84
$3.99
52-Week Range:
$2.53
$155.91
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
3.11 | 1.50M | 11.51M | -54.00M | -23.73M | -711.82 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Reven - GuruFocus
JAGX: Q1 2026 net revenue jumped 816% year-over-year, fueled by a major out-license agreement - TradingView
JAGX: Q1 2026 revenue jumped 816% year-over-year, fueled by a transformative licensing deal - TradingView
Earnings call transcript: Jaguar Health Q1 2026 revenue surges 816% By Investing.com - Investing.com Canada
Q1 2026 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health (JAGX) Q3 2025 Earnings Transcript - AOL.com
Jaguar Health, Inc. Announces Entry Into Material Definitive Exchange Agreements With Streeterville Capital, LLC - Minichart
Jaguar Health Inc (HAM:1JA1) Stock Price, Trades & News - GuruFocus
Jaguar Health (NASDAQ: JAGX) delays 2026 meeting after Nasdaq talks - Stock Titan
JAGX Stock Price, Quote & Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health Inc stock (US47010C1053): Q1 2026 revenue surge draws volatile market reaction - AD HOC NEWS
JAGX Sees Dramatic Revenue Surge in Q1 2026 - GuruFocus
JAGX Financials: Income Statement, Balance Sheet & Cash Flow | Jaguar Health Inc - Stock Titan
Jaguar Health Reports First Quarter 2026 Financials - ACCESS Newswire
JAGX: Net revenue jumped 816% year-over-year, fueled by a major licensing deal and strategic refocus - TradingView
Jaguar Health reports Q1 2026 revenue up 816% to $20.3M, operating income $10.2M - TradingView
Jaguar Health licenses U.S. Mytesi rights in $19M Q1 deal - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Jaguar Health (NASDAQ: JAGX) posts 816% Q1 2026 revenue surge - Stock Titan
JAGUAR HEALTH ($JAGX) Releases Q1 2026 Earnings - Quiver Quantitative
Jaguar Health, Inc. 1Q 2026: Revenue $20.3M, Net income $8.72M, EPS $(13.60) — 10-Q Summary - TradingView
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Jaguar Health (JAGX) turns Q1 profit but flags going concern risks - Stock Titan
Jaguar (JAGX) Q4 2025 Earnings Transcript - The Globe and Mail
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference - ACCESS Newswire
Jaguar Health: May 26 Q1 webcast, CEO at May 28 Lytham event - Stock Titan
Jaguar Health, Inc. Announces Series Q Preferred Stock Exchange Agreements and Related SEC Filing Details - Minichart
Jaguar Animal Health Issues Series Q Preferred Stock - TipRanks
Jaguar Health Exchanges Series Q Preferred to Cut $22.7 Million in Royalty Obligations - TradingView
Jaguar Health (NASDAQ: JAGX) cuts $22.7M royalties via new Series Q preferred - Stock Titan
Jaguar Health (JAGX) Initiates Key Pediatric Clinical Trial Phas - GuruFocus
Jaguar Health | DEFA14A: Others - Moomoo
Jaguar Health’s crofelemer trial advances for rare pediatric disease - Investing.com
Jaguar Health’s crofelemer trial advances for rare pediatric disease By Investing.com - Investing.com India
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer - Yahoo Finance
Jaguar Health stock surges on FDA breakthrough discussions for rare disease therapy - MSN
Jaguar Health Delays Quarterly Filing Briefly - TipRanks
Jaguar Health (NASDAQ: JAGX) delays Q1 2026 10-Q, cites subsequent events - Stock Titan
JAGX Stock Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health, Inc.Common Stock (NQ: JAGX - FinancialContent
Jaguar Health stock (US47010C1053): volatile biotech name in focus after latest financing moves - AD HOC NEWS
About Us | Cabling Installation & MaintenanceJaguar Health, Inc.Common Stock (Nasdaq:JAGX) Stock Quote - FinancialContent
JAGX Q1'26 Earnings: EPS estimate is (71.40) USD - TradingView
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split - ACCESS Newswire
Jaguar Health Inc (HAM:1JA1) Valuation - GuruFocus
Jaguar Health (HAM:1JA1) Net Intangibles Purchase And Sale : €0.00 Mil (TTM As of Dec. 2025) - GuruFocus
Jaguar Health Inc Stock Historical Valuations | HAM:1JA1 - GuruFocus
Who's Buying or Selling Jaguar Health Inc (HAM:1JA1) Stock Today? - GuruFocus
Jaguar Health Inc (HAM:1JA1) DCF Valuation - GuruFocus
Jaguar Health Inc Stock Baskets | HAM:1JA1 - GuruFocus
Q3 2024 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):